Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid ( www.adherex.com )
Adherex Technologies Inc.
4620 Creekstone Drive Suite 200
Durham, North Carolina 27703
USA
Tel: (919) 484-8484
Fax: (919) 484-8001